University of Texas Develops Less Expensive Vaccine Production & Storage Process
Researchers have developed a less expensive way to produce vaccines that cuts the costs of vaccine production and storage by up to 80 percent without decreasing safety or effectiveness.
Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations, said these University of Texas Medical Branch at Galveston (UTMB) researchers in a press release.
In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics.
In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
"The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development," said UTMB's Pei-Yong Shi, Ph.D., professor in the department of biochemistry and molecular biology.
"Importantly, this vaccine technology could potentially serve as a universal platform for the development of live-attenuated vaccines for many viral pathogens."
To achieve these goals, the UTMB research team engineered a live-attenuated Zika vaccine in the DNA form.
Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity.
With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories.
Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB's Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice.
After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
"This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity," Dr. Shi said.
"We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses."
Funders were the National Institute of Health, Kleberg Foundation, Centers for Disease Control and Prevention, University of Texas Medical Branch. No conflicts of interest were disclosed by these researchers. Other authors include UTMB's Jing Zou, Xuping Xie, Huanle Luo, Chao Shan, Antonio Muruato, Scott Weaver and Tian Wang.
The findings are currently available in EBioMedicine.